Page last updated: 2024-11-03

risperidone and Obesity, Morbid

risperidone has been researched along with Obesity, Morbid in 1 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahmed, H1
Ali, H1

Other Studies

1 other study available for risperidone and Obesity, Morbid

ArticleYear
Risperidone induced weight gain leading to benign intracranial hypertension.
    BMJ case reports, 2011, Jul-27, Volume: 2011

    Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Obesity, Morbid; Pseudotumor Cerebri; Risper

2011